^
    1m
    Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody-Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat. (PubMed, J Clin Med)
    Cumulatively, these therapies illustrate both the progress and the ongoing challenges of biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic sequencing, and variability in evidence maturity across targeted strategies. While pirtobrutinib and brentuximab vedotin are supported by increasingly robust clinical evidence in selected lymphoma subtypes, the role of belinostat remains constrained by modest response rates and limited randomized data, underscoring the continued need for biomarker refinement and more precisely individualized therapeutic approaches in NHL precision medicine.
    Review • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    Adcetris (brentuximab vedotin) • Jaypirca (pirtobrutinib) • Beleodaq (belinostat)
    2ms
    Reversing Bladder Cancer Chemo-resistance through Blocking Cell Senescence by a Combination Therapy. (PubMed, Theranostics)
    A co-delivery therapeutic strategy combining the pan-HDAC inhibitor belinostat (PXD101) with paclitaxel (PTX) was developed and evaluated in patient-derived cisplatin-resistant organoids and a platinum-refractory patient-derived xenograft (PDX) model. Modulation of p21 influenced cell-cycle re-entry, senescence burden, and responsiveness to PTX. These findings define an HDAC-p21-senescence axis that sustains chemoresistance in bladder cancer and provide preclinical evidence supporting combined epigenetic and antimitotic therapy as a strategy to overcome acquired drug tolerance.
    Journal
    |
    HDAC1 (Histone Deacetylase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    cisplatin • paclitaxel • Beleodaq (belinostat)
    3ms
    RESOLVE: Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, University of Utah | Trial primary completion date: Apr 2026 --> Aug 2026
    Trial primary completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Beleodaq (belinostat)
    4ms
    Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma (clinicaltrials.gov)
    P3, N=150, Recruiting, Corvus Pharmaceuticals, Inc. | Trial completion date: Jul 2028 --> Dec 2028 | Trial primary completion date: Nov 2026 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    Beleodaq (belinostat) • Folotyn (pralatrexate) • soquelitinib (CPI-818)
    4ms
    Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Jan 2027 --> Dec 2025
    Trial primary completion date
    |
    Mektovi (binimetinib) • Beleodaq (belinostat)
    5ms
    Tracing the Analytical Footprint of Belinostat: Exploring Pharmacology and Synthetic Framework. (PubMed, Biomed Chromatogr)
    Belinostat and its potential metabolites have often been qualitatively and quantitatively estimated and tracked using several analytical methods including UPLC-MS/MS, HPLC-UV, FTIR, TLC, NMR, and ESI-MS. In terms of therapeutic use of belinostat, this review demonstrates how important it is to understand the metabolism and degradation pathways of belinostat, as well as possible drug-drug interactions.
    Review • Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    Beleodaq (belinostat)
    5ms
    ETCTN 10500: Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
    |
    RAS wild-type • EZH2 mutation
    |
    Tazverik (tazemetostat) • Beleodaq (belinostat)
    5ms
    Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma (clinicaltrials.gov)
    P2, N=15, Completed, University of Miami | Active, not recruiting --> Completed
    Trial completion
    |
    IFNA1 (Interferon Alpha 1)
    |
    cyclophosphamide • Beleodaq (belinostat)
    5ms
    ETCTN: Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma (clinicaltrials.gov)
    P2, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jan 2027
    Trial completion date
    |
    Inqovi (decitabine/cedazuridine) • Beleodaq (belinostat) • guadecitabine (SGI-110)
    6ms
    RESOLVE: Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, University of Utah | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Beleodaq (belinostat)
    7ms
    Comprehensive Analysis to Reveal Nitrogen Metabolism-Associated Genes as a Prognostic Index in Head and Neck Squamous Cell Cancer. (PubMed, Curr Med Chem)
    Our study established a NM-related gene signature closely linked to immune microenvironment and drug sensitivity, highlighting potential biomarkers and therapeutic targets for prognosis and personalized therapy in HNSCC.
    Journal
    |
    SLC7A5 (Solute Carrier Family 7 Member 5) • HPRT1 (Hypoxanthine Phosphoribosyltransferase 1)
    |
    erlotinib • gefitinib • Beleodaq (belinostat)
    9ms
    A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) (clinicaltrials.gov)
    P3, N=218, Recruiting, Dizal Pharmaceuticals
    New P3 trial
    |
    gemcitabine • Epidaza (chidamide) • Beleodaq (belinostat) • Folotyn (pralatrexate) • golidocitinib (DZD4205)